Best practice in the prevention and management of paediatric respiratory syncytial virus infection

Therapeutic Advances in Infectious Disease

Volumn 3, Issue 2, 2015, Pages 63-71

  Drysdale, Simon B ^a   Green, Christopher A ^a   Sande, Charles J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

bronchiolitis; infant; nosocomial infection; palivizumab; RSV

Indexed keywords

ADRENALIN; ANTIBIOTIC AGENT; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID DERIVATIVE; HELIOX; IPRATROPIUM BROMIDE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; PALIVIZUMAB; PRESATOVIR; RESPIRATORY SYNCYTIAL VIRUS VACCINE; RIBAVIRIN; SALBUTAMOL;

BRONCHIOLITIS; CLINICAL TRIAL (TOPIC); GENETIC PREDISPOSITION; HUMAN; META ANALYSIS (TOPIC); OXYGEN SUPPLY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHYSIOTHERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY SYNCYTIAL VIRUS INFECTION; REVIEW;

EID: 85007425997     PISSN: 20499361     EISSN: 2049937X     Source Type: Journal    
DOI: 10.1177/2049936116630243     Document Type: Review

References (74)

1. American Academy of Pediatrics (2006) Diagnosis and management of bronchiolitis. Pediatrics118: 1774–1793.
2. E.BaraldiM.LanariP.ManzoniG.RossiS.VandiniA.Rimini (2014) Inter-society consensus document on treatment and prevention of bronchiolitis in newborns and infants. Ital J Pediatr40: 65.
3. M.BlankenM.RoversJ.MolenaarP.Winkler-SeinstraA.MeijerJ.Kimpen (2013) Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. New Engl J Med368: 1791–1799.
4. J.DeVincenzoH.FathiM.McClureC.WestlandS.ChandaR.Lambkin-Williams (2014a) Treatment with oral ALS-008176, a nucleoside analog, rapidly reduces RSV viral load and clinical disease severity in a healthy volunteer challenge study. Open Forum Infect Dis1(Suppl. 1): S66–S69.
5. J.DeVincenzoR.Lambkin-WilliamsT.WilkinsonJ.CehelskyS.NochurE.Walsh (2010) A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus. Proc Natl Acad Sci USA107: 8800–8805.
6. J.DeVincenzoR.WhitleyR.MackmanC.Scaglioni-WeinlichL.HarrisonE.Farrell (2014b) Oral GS-5806 activity in a respiratory syncytial virus challenge study. N Engl J Med371: 711–722.
7. J.DohertyD.BrookfieldJ.GrayR.McEwan (1998) Cohorting of infants with respiratory syncytial virus. J Hosp Infect38: 203–206.
8. S.DrysdaleM.PrendergastM.AlcazarT.WilsonM.SmithM.Zuckerman (2014) Genetic predisposition of RSV infection-related respiratory morbidity in preterm infants. Eur Pediatr173: 905–912.
9. S.DrysdaleT.WilsonM.AlcazarS.BroughtonM.ZuckermanM.Smith (2011) Lung function prior to viral lower respiratory tract infections in prematurely born infants. Thorax66: 468–473.
10. M.EverardD.HindK.UgonnaJ.FreemanM.BradburnS.Dixon (2015) Saline in acute bronchiolitis RCT and economic evaluation: hypertonic saline in acute bronchiolitis – randomised controlled trial and systematic review. Health Technol Assess19: 1–130.
11. R.FarleyS.GkpL.ErikssonC.Del Mar (2014) Antibiotics for bronchiolitis in children under two years of age. Cochrane Database Syst Rev10: CD005189.
12. T.FeltesA.CabalkaH.MeissnerF.PiazzaD.CarlinF.Top (2003) Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr143: 532–540.
13. Fernandes, R., Bialy, L., Vandermeer, B., Tjosvold, L., Plint, A., Patel, H. et al. (2010) Glucocorticoids for acute viral bronchiolitis in infants and young children. Cochrane Database Syst Rev (10): CD004878
14. V.FlahermanS.LiA.RaginsA.MasaquelP.KipnisG.Escobar (2010) Respiratory syncytial virus testing during bronchiolitis episodes of care in an integrated health care delivery system: a retrospective cohort study. Clin Ther32: 2220–2229.
15. J.FriedmanM.RiederJ.Walton. Canadian Paediatric Society, Acute Care Committee, Drug Therapy and Hazardous Substances Committee (2014) Bronchiolitis: recommendations for diagnosis, monitoring and management of children one to 24 months of age. Paediatr Child Health19: 485–491.
16. Gadomski, A. and Scribani, M. (2014) Bronchodilators for bronchiolitis. Cochrane Database Syst Rev (6): CD001266
17. Glenn, G., Fries L., Thomas D., Smith G., Kpamegan E., Lu, H. et al. (2015) A randomized, blinded, controlled, dose-ranging study of a respiratory syncytial virus recombinant fusion (F) nanoparticle vaccine in healthy women of childbearing age. J Infect Dis 10 August (epub ahead of print)
18. G.GlennG.SmithL.FriesR.RaghunandanH.LuB.Zhou (2013) Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine. Vaccine31: 524–532.
19. C.GreenE.ScarselliC.SandeA.ThompsonC. De LaraK.Taylor (2015a) Chimpanzee adenovirus – and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults. Sci Transl Med7: 300ra126.
20. Green, C., Yeates, D., Goldacre, A., Sande, C., Parslow, R., McShane, P. et al. (2015b) Admission to hospital for bronchiolitis in England: trends over five decades, geographical variation and association with perinatal characteristics and subsequent asthma. Arch Dis Child 4 September (epub ahead of print)
21. J.GroothuisJ.BaumanF.MalinoskiM.Eggleston (2008) Strategies for prevention of RSV nosocomial infection. J Perinatol28: 319–323.
22. C.Hall (2001) Respiratory syncytial virus and parainfluenza virus. N Engl J Med344: 1917–1928.
23. C.HallR.DouglasJ.Geiman (1980) Possible transmission by fomites of respiratory syncytial virus. J Infect Dis141: 98–102.
24. C.HallJ.GeimanR.DouglasJr.M.Meagher (1978) Control of nosocomial respiratory syncytial viral infections. Pediatrics62: 728–732.
25. C.HallK.PowellK.SchnabelC.GalaP.Pincus (1988) Risk of secondary bacterial infection in infants hospitalized with respiratory syncytial viral infection. J Pediatr113: 266–271.
26. C.HallG.WeinbergM.IwaneA.BlumkinK.EdwardsM.Staat (2009) The burden of respiratory syncytial virus infection in young children. N Engl J Med360: 588–598.
27. Hartling, L., Bialy, L., Vandermeer, B., Tjosvold, L., Johnson, D., Plint, A. et al. (2011) Epinephrine for bronchiolitis. Cochrane Database Syst Rev (6): CD003123
28. G.Humphreys (2015) Hubs to spread technology and save lives. Bull World Health Organ93: 290–291.
29. P.JacobsD.LierK.GoochK.BueschM.LorimerI.Mitchell (2013) A model of the costs of community and nosocomial pediatric respiratory syncytial virus infections in Canadian hospitals. Can J Infect Dis Med Microbiol24: 22–26.
30. R.JanssenL.BontC.SiezenH.HodemaekersM.ErmersG.Doornbos (2007) Genetic susceptibility to respiratory syncytial virus bronchiolitis is predominantly associated with innate immune genes. J Infect Dis196: 826–834.
31. A.KapikianR.MitchellR.ChanockR.ShvedoffC.Stewart (1969) An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol89: 405–421.
32. L.KaranfilM.ConlonK.LykensC.MastersM.FormanM.Griffith (1999) Reducing the rate of nosocomially transmitted respiratory syncytial virus. Am J Infect Control27: 91–96.
33. T.KinyanjuiT.HouseM.KitiP.CaneD.NokesG.Medley (2015) Vaccine induced herd immunity for control of respiratory syncytial virus disease in a low-income country setting. PLoS ONE10: e0138018.
34. J.LangleyE.WangB.LawD.StephensF.BoucherS.Dobson (1997) Nosocomial respiratory syncytial virus infection in Canadian pediatric hospitals: a Pediatric Investigators Collaborative Network on Infections in Canada Study. J Pediatr131: 113–117.
35. Liet, J., Ducruet, T., Gupta, V. and Cambonie, G. (2010) Heliox inhalation therapy for bronchiolitis in infants. Cochrane Database Syst Rev (4): CD006915
36. F.LiuJ.OuyangA.SharmaS.LiuB.YangW.Xiong (2015) Leukotriene inhibitors for bronchiolitis in infants and young children. Cochrane Database Syst Rev3: CD010636.
37. R.LozanoM.NaghaviK.ForemanS.LimK.ShibuyaV.Aboyans (2012) Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet380: 2095–2128.
38. K.MacartneyM.GorelickM.ManningR.HodinkaL.Bell (2000) Nosocomial respiratory syncytial virus infections: the cost-effectiveness and cost-benefit of infection control. Pediatrics106: 520–526.
39. J.MansbachP.PiedraS.TeachF.AshleyT.ForgeyS.Clark (2012) Prospective, multicenter study of viral etiology and hospital length-of-stay in children with severe bronchiolitis. Arch Pediatr Adolesc Med166: 700–706.
40. D.McClureB.KiekeM.SundaramM.SimpsonJ.MeeceF.Sifakis (2014a) Seasonal incidence of medically attended respiratory syncytial virus infection in a community cohort of adults ≥50 years old. PLoS ONE9: 1–7.
41. D.McClureB.KiekeM.SundaramM.SimpsonJ.MeeceF.Sifakis (2014b) Seasonal incidence of medically attended respiratory syncytial virus infection in a community cohort of adults ≥50 years old. PLoS ONE9: e102586.
42. K.MeertS.HeidemannM.Lieh-laiA.Sarnaik (1989) Clinical characteristics of respiratory syncytial virus infections in healthy versus previously compromised host. Congenit Heart Dis170: 167–170.
43. H.Meissner (2016) Viral bronchiolitis in children. N Engl J Med374: 62–72.
44. E.MillerT.GebretsadikK.CarrollW.DupontY.MohamedL.Morin (2013) Viral etiologies of infant bronchiolitis, croup and upper respiratory illness during 4 consecutive years. Pediatr Emerg Care32: 950–955.
45. J.MillsJ.HarperD.BroomfieldK.Templeton (2011) Rapid testing for respiratory syncytial virus in a paediatric emergency department: Benefits for infection control and bed management. J Hosp Infect77: 248–251.
46. P.MunywokiD.KoechC.AgotiN.KibirigeJ.KipkoechP.Cane (2015) Influence of age, severity of infection, and co-infection on the duration of respiratory syncytial virus (RSV) shedding. Epidemiol Infect143: 804–812.
47. H.NairD.NokesB.GessnerM.DheraniS.MadhiR.Singleton (2010) Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet375: 1173–1181.
48. H.NairW.BrooksM.KatzA.RocaJ.BerkleyS.Madhi (2011) Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis. Lancet378: 1917–1930.
49. R.NennaM.FerraraA.NicolaiA.PierangeliC.ScagnolariP.Papoff (2015) Viral load in infants hospitalized for respiratory syncytial virus bronchiolitis correlates with recurrent wheezing at thirty-six-month follow-up. Pediatr Infect Dis J34: 1131–1132.
50. National Institute for Health and Care Excellence (NICE) (2015) Bronchiolitis: diagnosis and management of bronchiolitis in children. Clinical Guideline 9, London: NICE.
51. K.O’BrienA.ChandranR.WeatherholtzH.JafriM.GriffinT.Bellamy (2015) Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial. Lancet Infect Dis15: 1398–1408.
52. PATH (2015) PATH RSV vaccine snapshot July 2015. Available from: http://sites.path.org/vaccinedevelopment/files/2015/07/RSV-snapshot-July2015.pdf (accessed 19 January 2016)
53. A.PlintD.JohnsonH.PatelN.WiebeR.CorrellR.Brant (2009) Epinephrine and dexamethasone in children with bronchiolitis. N Engl J Med360: 2079–2089.
54. Public Health England (2015) Immunisation against infectious disease. The Green Book, London: Public Health England.
55. S.RalstonV.Hill (2009) Incidence of apnea in infants hospitalized with respiratory syncytial virus bronchiolitis: a systematic review. J Pediatr155: 728–733.
56. S.RalstonA.LieberthalH.MeissnerB.AlversonJ.BaleyA.Gadomski (2014) Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis. Pediatrics134: e1474–e1502.
57. C.ReedS.ChavesP.Daily KirleyR.EmersonD.AragonE.Hancock (2015) Estimating influenza disease burden from population-based surveillance data in the United States. PLoS ONE10: e0118369.
58. Roque I Figuls, M., Gine-Garriga, M., Granados Rugeles, C. and Perrotta, C. (2012) Chest physiotherapy for acute bronchiolitis in paediatric patients between 0 and 24 months old. Cochrane Database Syst Rev (1): CD004873
59. B.SchepensL.IbanezS.De BaetsA.HultbergP.BogaertP.De Bleser (2011) Nanobodies® specific for respiratory syncytial virus fusion protein protect against infection by inhibition of fusion. J Infect Dis204: 1692–1701.
60. Scottish Intercollegiate Guideline Network (2006) Bronchiolitis in children. Sign Guideline 91, Edinburgh: SIGN.
61. E.Simoes (2003) Environmental and demographic risk factors for respiratory syncytial virus lower respiratory tract disease. J Pediatr143: S118–S126.
62. A.SimonA.MüllerK.KhuranaS.EngelhartM.ExnerO.Schildgen (2008) Nosocomial infection: a risk factor for a complicated course in children with respiratory syncytial virus infection – results from a prospective multicenter German surveillance study. Int J Hyg Environ Health211: 241–250.
63. R.SteinD.SherrillW.MorganC.HolbergM.HalonenL.Taussig (1999) Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Lancet354: 541–545.
64. Stollar, F., Alcoba, G., Gervaix, A. and Argiroffo, C. (2014) Virologic testing in bronchiolitis: does it change management decisions and predict outcomes? Eur J Pediatr 1429–1435
65. The IMpact-RSV Study Group (1998) Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics102: 531–537.
66. R.ThibeaultR.GilcaS.CôtéG.De SerresG.BoivinE.Déry (2007) Antibiotic use in children is not influenced by the result of rapid antigen detection test for the respiratory syncytial virus. J Clin Virol39: 169–174.
67. K.ThorburnS.KerrN.TaylorH.van Saene (2004) RSV outbreak in a paediatric intensive care unit. J Hosp Infect57: 194–201.
68. T.TurnerB.KoppG.PaulL.LandgraveD.HayesR.Thompson (2014) Respiratory syncytial virus: current and emerging treatment options. ClinicoEconom Outcomes Res6: 217–225.
69. Ventre, K. and Randolph, A. (2007) Ribavirin for respiratory syncytial virus infection of the lower respiratory tract in infants and young children. Cochrane Database Syst Rev (1): CD000181
70. A.WeberM.WeberP.Milligan (2001) Modeling epidemics caused by respiratory syncytial virus (RSV). Math Biosci172: 95–113.
71. R.Welliver (2007) Temperature, humidity, and ultraviolet B radiation predict community respiratory syncytial virus activity. Pediatr Infect Dis J26(11 Suppl.): S29–S35.
72. K.WidmerM.GriffinY.ZhuJ.WilliamsH.Talbot (2014) Respiratory syncytial virus- and human metapneumovirus-associated emergency department and hospital burden in adults. Influenza Other Respir Viruses8: 347–352.
73. L.ZhangR.Mendoza-SassiT.KlassenC.Wainwright (2015) Nebulized hypertonic saline for acute bronchiolitis: a systematic review. Pediatrics136: 687–701.
74. K.Zomer-KooijkerC.UiterwaalA.van der GugtenB.WilbrinkL.BontC.van der Ent (2014) Decreased lung function precedes severe respiratory syncytial virus infection and post-respiratory syncytial virus wheeze in term infants. Eur Resp J44: 666–674.